RxDoctor Payments DataLook up a doctor →

John Boswell, MD

Dermatology · Fresno, CANPI 1295936961

Payments from drug & device makers

$845,443in general payments, 2019–2025

Across 1,659 payments — averaging $509.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$205K
  • Sanofi$105K
  • Johnson & Johnson$76K
  • Regeneron Healthcare Solutions, Inc.$75K
  • Bausch Health US, LLC$68K
  • Dermavant Sciences, Inc.$58K
  • plus $258K from 36 others

What the payments were for

  • Consulting fees$36,2675%
  • Speaking & faculty fees$677,36787%
  • Travel & lodging$32,9754%
  • Food & beverage$30,1404%
  • Education$6280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$845,443 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$1,146,836
Medicare patients
2,903
Services billed
18,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab124$457,951
Skyrizi PenRisankizumab-Rzaa13$290,360
OtezlaApremilast17$119,303
Cosentyx Unoready PenSecukinumab16$115,465
RinvoqUpadacitinib16$101,248
Cosentyx Sensoready (2 Pens)Secukinumab14$100,980
Dupixent SyringeDupilumab21$78,582
Acitretin16$11,128
Clobetasol Propionate204$9,243
Fluorouracil127$7,970
Mycophenolate Mofetil33$3,237
Ketoconazole202$2,723
Tacrolimus15$2,672
ValacyclovirValacyclovir Hcl64$2,329
Doxycycline Hyclate70$2,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$665$119,30317 claims
AbbVieRinvoq$204,931$101,24816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →